Previous 10 | Next 10 |
2023-09-11 09:49:45 ET The selling stockholders of UroGen Pharma ( NASDAQ: URGN ) plans to sell 12.6 million common shares as part of a secondary offering, the company disclosed in an SEC filing on Friday after the bell. The company said it was not selling any ordina...
IRVINE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of James Robinson to its Board of Directors effective October 1, 2023. Mr. Robinson is a seasoned biopharmaceutical executive with over 30 years ...
2023-08-17 10:07:42 ET Gainers: CervoMed ( CRVO ) +86% . Tivic Health Systems ( TIVC ) +34% . Jupiter Wellness ( JUPW ) +11% . NEXGEL ( NXGL ) +9% . Kamada ( KMDA ) +8% . Losers: Check-Cap ( CHEK ) -23% . ...
2023-08-10 13:57:10 ET UroGen Pharma Ltd. (URGN) Q2 2023 Results Conference Call August 10, 2023 10:00 AM ET Company Participants Vincent Perrone - Head Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer...
2023-08-10 08:02:19 ET UroGen Pharma press release ( NASDAQ: URGN ): Q2 GAAP EPS of -$1.03 beats by $0.10 . Revenue of $21.14M (+27.3% Y/Y) beats by $1.02M . Reported record JELMYTO® net product revenues in Q2 2023 of $21.1 million, an increase of ~27% fro...
Both ENVISION and ATLAS Phase 3 trials of UGN-102 met primary endpoints in treating low-grade intermediate-risk non‐muscle‐invasive bladder cancer (LG-IR-NMIBC). Reported record JELMYTO® net product revenues in Q2 2023 of $21.1 million, an increase of ~27% from the ...
-- Phase 3 ATLAS Clinical Trial Shows UGN-102 Demonstrated Superiority to TURBT with a 55% Reduction of Risk for Recurrence, Progression or Death in Patients who Received UGN-102 -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing no...
Conference Call and Webcast Scheduled for Thursday, August 10, 2023 at 10:00 AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report secon...
2023-08-02 10:45:00 ET Summary The US stock market (using the Russell 3,000 as a proxy) has now seen an increase in market cap of roughly $10 trillion from its bear market low last October through the end of July 2023. the peak market cap for the US stock market was $51.5 trillion...
UroGen Pharma Ltd. (NASDAQ: URGN) is one of today's top gainers. The company's shares are currently up 26.66% on the day to $22.66. UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It of...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to m...